February 17, 2023 | Product Awareness

Elimination of the DATA-Waiver Program: How will it Impact the Opioid Crisis?

Read More

Have you heard about the signing of the Consolidated Appropriations Act of 2023?

With this Act, Congress eliminated the DATA-Waiver Program. This means:

• A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.

• There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.

• All prescriptions for buprenorphine only require a standard DEA registration number.

Subscribe

Rxpert Solutions gives you access to a pharmacist with years of hospital pharmacy experience, an outside perspective, and a passion for finding practical and lasting solutions to improving medication safety.

Profile Website

This post is related to:

Opioid Stewardship & Drug Diversion Prevention